COMP <GO>
HSIC vs CAI // ALTMAN Z-SCORE & DEBT/EQUITY
Henry Schein Inc. (NASDAQ) VS. Caris Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: HSIC 4
— CAI 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: CAI
LAST: $84.88 (-1.80%) • MKT CAP: $9.63B
balance-sheet
2.81
LAST: $34.33 (-5.01%) • MKT CAP: $10.21B
balance-sheet
9.79
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HSIC VS. CAI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HSIC | CAI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 31.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.20% | 4.40% | +6.80 | HSIC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.5x | 95.0x | -85.50 | HSIC | /valuation <GO> |
| Free Cash Flow Yield | 1.23% | 0.65% | +0.58 | HSIC | /fcf-yield <GO> |
| Operating Margin | 5.00% | 5.60% | -0.60 | CAI | /operating-margins <GO> |
| Net Profit Margin | 3.20% | -8.40% | +11.60 | HSIC | /net-margins <GO> |
| Revenue Growth (YoY) | 4.00% | 97.00% | -93.00 | CAI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.81 | 9.79 | -6.98 | CAI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | CAI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.9 | 67.6 | -13.70 | CAI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.91 | -0.02 | CAI | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.4x | 21.0x | +0.40 | CAI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.63B | $10.21B | -$579.6M | CAI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HSIC REV | CAI REV | HSIC GROSS % | CAI GROSS % | HSIC FCF | CAI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.18B | $812.0M | 31.1% | — | $118.7M | $66.9M |
| FY 2024 | $12.67B | $412.3M | 31.7% | — | $277.7M | -$253.6M |
| FY 2023 | $12.34B | $306.1M | — | — | -$55.3M | -$289.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HSIC // BETA 0.89
CAI // BETA 0.91